Quick Answer
NEKTAR THERAPEUTICS reported Diluted EPS of $9.73 per share (loss) for fiscal year 2025.
NEKTAR THERAPEUTICS Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$9.73 | -12.1% |
| 2024 | -$8.68 | -498.6% |
| 2023 | -$1.45 | +26.4% |
| 2022 | -$1.97 | +31.1% |
| 2021 | -$2.86 | -14.9% |
| 2020 | -$2.49 | +1.2% |
| 2019 | -$2.52 | -166.7% |
| 2018 | $3.78 | +709.7% |
| 2017 | -$0.62 | +43.6% |
| 2016 | -$1.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.87 | +29.7% | +36.6% |
| June 30, 2025 | -$2.95 | +21.5% | -1129.2% |
| March 31, 2025 | -$0.24 | -26.3% | +91.0% |
| September 30, 2024 | -$2.66 | -1008.3% | +29.3% |
| June 30, 2024 | -$3.76 | -1292.6% | -1878.9% |
| March 31, 2024 | -$0.19 | +74.0% | +20.8% |
| September 30, 2023 | -$0.24 | +22.6% | +11.1% |
| June 30, 2023 | -$0.27 | +68.2% | +63.0% |
- NEKTAR THERAPEUTICS showed a decrease of -12.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, NEKTAR THERAPEUTICS’s diluted eps has declined by 784.5% (from $1.10 per share (loss) to $9.73 per share (loss)).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: